Stockhouse

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID ...